Bluejay Diagnostics, Inc. Common Stock
BJDXBlueJay Diagnostics, Inc. (BJDX) is a biotechnology company focused on developing innovative diagnostic solutions for infectious diseases. The company's technology aims to enable rapid, accurate, and cost-effective detection of various pathogens, enhancing clinical decision-making and patient outcomes. Bluejay Diagnostics leverages advanced molecular and digital health methodologies to advance point-of-care testing and improve healthcare efficiency.
Company News
Bluejay Diagnostics closed a private placement raising $8.5 million upfront with up to $15.2 million in potential additional proceeds from warrant exercises. The company plans to use net proceeds for FDA approval efforts, R&D activities, and working capital, with cash runway expected to extend into Q1 2027 and potentially beyond FDA approval if w...
Bluejay Diagnostics (BJDX) shares traded down 1.84% on Wednesday despite positive developments. The company announced a private placement raising up to $23.6 million ($8.5M upfront plus $15.1M from warrant exercises) to extend cash runway into early 2027 ahead of FDA submission. The company also partnered with Argonaut Manufacturing Services to e...
Bluejay Diagnostics, Inc. announced that an abstract related to its Symphony IL-6 Test has been accepted for presentation at the 2025 SAEM Annual Meeting. The presentation will focus on results from the SYMON-I pilot clinical study, which evaluated IL-6 as a prognosticator for sepsis patients.
ACTON, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of a firm commitment underwritten public offering wi...
Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days after sepsis and septic shock diagnosis and are admitted to the intensive care unit (ICU). Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor o...
